Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Arbutus Biopharma Corp (ABUS)
Price$5.15Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M | $6.9M | $6.0M | $5.9M | $10.7M | $1.5M | $23.3M | $15.0M | $15.5M | $14.1M | $16.8M | — |
| Research & development | $25.2M | $54.0M | $73.7M | $84.4M | $65.5M | $49.3M | $57.6M | $57.9M | $62.7M | $61.3M | $51.5M | $38.7M | $21.5M | $18.0M | $20.1M | — |
| Operating expenses | $52.2M | $82.5M | $96.2M | $104.5M | $84.5M | $64.7M | $149.9M | $95.7M | $121.6M | $493.1M | $127.2M | $48.4M | $27.6M | $27.1M | $27.5M | — |
| Operating income | −$38.2M | −$76.3M | −$78.1M | −$65.5M | −$73.5M | −$57.8M | −$143.9M | −$89.8M | −$110.9M | −$491.6M | −$103.9M | −$33.4M | −$12.2M | −$12.9M | −$10.7M | — |
| Operating margin | −270.96% | −1,236.74% | −430.53% | −167.75% | −669.11% | −836.07% | −2,393.96% | −1,510.18% | −1,036.73% | −32,973.78% | −446.46% | −223.59% | −78.58% | −91.78% | −63.61% | — |
| EBITDA | −$37.8M | −$74.9M | −$76.7M | −$64.0M | −$71.8M | −$55.8M | −$141.9M | −$87.6M | −$108.9M | −$490.5M | −$103.3M | −$32.9M | −$11.5M | −$12.1M | −$9.7M | — |
| EBITDA margin | −268.39% | −1,214.37% | −422.79% | −164.10% | −653.16% | −807.46% | −2,360.22% | −1,473.49% | −1,017.79% | −32,900.54% | −443.93% | −220.06% | −74.61% | −85.64% | −57.74% | — |
| Net income | −$33.5M | −$69.9M | −$72.8M | −$69.5M | −$76.2M | −$63.7M | −$153.7M | −$57.1M | −$84.4M | −$384.2M | −$62.7M | −$38.8M | −$14.1M | $29.6M | −$10.1M | — |
| Net profit margin | −237.88% | −1,133.04% | −401.57% | −178.01% | −693.91% | −921.97% | −2,557.36% | −959.80% | −788.91% | −25,765.53% | −269.45% | −259.73% | −90.93% | 209.93% | −59.98% | — |
| Basic EPSper basic share | -$0.17 | -$0.38 | -$0.44 | -$0.46 | -$0.83 | -$1.00 | -$2.89 | -$1.21 | -$1.56 | -$7.24 | -$1.38 | -$1.80 | -$0.92 | $2.16 | -$0.89 | — |
| Diluted EPSper diluted share | -$0.17 | -$0.38 | -$0.44 | -$0.46 | -$0.83 | -$1.00 | -$2.89 | -$1.21 | -$1.56 | -$7.24 | -$1.38 | -$1.80 | -$0.92 | $2.07 | -$0.89 | — |
Owners
Reported shareholders
≈19.66%of listed shares
Gline Matthew38.85M shares · Feb 24, 2025
View holders
| Holder | % owned |
|---|---|
Gline Matthew | ≈19.66%38.85M shares |
Two Seas Capital LP | 9.66%19.1M shares |
MORGAN STANLEY | 8.96%17.7M shares |
Whitefort Capital Management, LP | 7.99%15.79M shares |
BlackRock, Inc. | 6.97%13.77M shares |
STATE STREET CORP | 3.98%7.87M shares |
Rubric Capital Management LP | 3.81%7.53M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.55%7.01M shares |
BARCLAYS PLC | 2.13%4.21M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.08%4.12M shares |
GOLDMAN SACHS GROUP INC | 1.77%3.51M shares |
BANK OF AMERICA CORP /DE/ | 1.34%2.65M shares |
BlackBarn Capital Partners LP | 1.26%2.5M shares |
Legal & General Group Plc | 1.25%2.47M shares |
Woodline Partners LP | 1.15%2.28M shares |
Jefferies Financial Group Inc. | 0.87%1.71M shares |
McElhaugh Michael J. | ≈0.84%1.66M shares |
NOMURA HOLDINGS INC | 0.83%1.64M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.78%1.54M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.72%1.43M shares |
Percentages use 197.63M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 4, 2025Form 4 · 10b5-1 | HASTINGS DAVID CChief Financial Officer | SellCommon Shares | 22.2K | $3.28 | $72.8K | 159.7K |
| Feb 4, 2025Form 4 · 10b5-1 | Sims KarenChief Medical Officer | SellCommon Shares | 19.3K | $3.28 | $63.5K | 106.2K |
| Feb 4, 2025Form 4 · 10b5-1 | McElhaugh Michael J.Interim President & CEO | SellCommon Shares | 23.8K | $3.28 | $78.0K | 1.48M |
| Feb 4, 2025Form 4 · 10b5-1 | Naftzger J. ChristopherGeneral Counsel and CCO | SellCommon Shares | 11.3K | $3.28 | $37.2K | 86.2K |
| Aug 14, 2024Form 4 | MANCHESTER KEITH SDirector | SellCommon Shares | 8.8K | $3.69 | $32.6K | 46.1K |